Zeo ScientifiX Appoints Dr. John D. Kisiday as Chief Science Officer
Summary
Zeo ScientifiX, Inc. appointed Dr. John D. Kisiday, Ph.D., a veteran in tissue engineering and regenerative medicine, as its new Chief Science Officer, effective January 23, 2026.
Key Events
-
Appointment of Chief Science Officer
Dr. John D. Kisiday, Ph.D., with almost 30 years of experience in tissue engineering and regenerative medicine, was appointed Chief Science Officer, effective January 23, 2026.
-
Compensation Package Details
Dr. Kisiday will receive an annual base salary of $175,000 and a grant of 50,000 shares of common stock, vesting over two years. He is also eligible for additional compensation for bringing commercially viable new products or business opportunities to the company.
-
Strategic Alignment
This key scientific hire follows the company's recent strategic partnership announcement on January 7, 2026, and aims to bolster its capabilities in product development and commercialization within the life sciences sector.
Analysis
This appointment significantly strengthens Zeo ScientifiX's scientific leadership, bringing nearly 30 years of experience in tissue engineering and regenerative medicine to the company. Dr. Kisiday's expertise is crucial for advancing the company's research initiatives and commercializing new therapies, aligning with recent strategic partnerships announced on January 7, 2026. His compensation package, including a substantial stock grant and potential for additional compensation for new product development, incentivizes growth and innovation in a key scientific role for this nano-cap life sciences company.
At the time of this filing, ZEOX was trading at $2.57 on OTC in the Life Sciences sector, with a market capitalization of approximately $16.8M. The 52-week trading range was $1.20 to $3.81. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.